Skip to content
Pfizer will have data on the efficacy of its vaccine against the new variant of COVID-19 in two weeks


Pfizer company logo (EFE / EPA / OLIVIER HOSLET / ARCHIVE)

The German Laboratory BioNTech, ally of Pfizer, expect to have at the latest “in two weeksthe first results of the studies that will determine if the new variant of COVID-19 detected in South Africa is capable of escaping the protection of the vaccinea spokeswoman said.

We have immediately launched studies on variant B.1.1.529“, that “clearly differs from known variants because it has additional mutations in the spike protein“Characteristic of the SARS-Cov-2 virus, the spokeswoman explained to the news agency AFP.

Pfizer and BioNTech prepared several months ago to adjust their vaccine in less than six weeks and deliver the first doses in 100 days.”If a variant was resistant.

News in development

Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.